Cerebrovascular Safety of Novel Migraine Biologics

Abstract

Migraine is a complex neurovascular disorder with significant global disease burden. The recent advent of monoclonal antibody therapies targeting the calcitonin gene-related peptide (CGRP) pathway has revolutionized prophylactic migraine management. However, concerns about the cerebrovascular safety profile of these novel biologics persist, given the vasoregulatory role of CGRP. This review critically appraises the current evidence regarding the cerebrovascular safety of CGRP-targeted biologics, emphasizing epidemiological data, mechanistic insights, risk stratification, and clinical implications for healthcare providers.

Introduction

Migraine affects approximately 1 in 7 individuals globally, representing a leading cause of disability. While traditional preventive therapies have limitations such as suboptimal efficacy and tolerability, monoclonal antibodies targeting the CGRP ligand or receptor offer a new paradigm in migraine prophylaxis. With increasing clinical adoption, it is imperative to understand the cerebrovascular safety of these agents, particularly in populations at risk for stroke and other vascular events.

Epidemiology / Disease Burden

Migraine is responsible for significant morbidity, ranking as the second leading cause of years lived with disability worldwide. It disproportionately affects women and individuals in their most productive years. The association between migraine, specifically migraine with aura, and an elevated risk of ischemic stroke has been well established in large epidemiological studies. These findings underscore the necessity for safe and effective preventive therapies that do not further exacerbate cerebrovascular risk.

Pathophysiology

The pathophysiology of migraine is multifactorial, involving trigeminovascular system activation, neurogenic inflammation, and cortical spreading depression. CGRP, a potent vasodilatory neuropeptide, plays a central role in migraine pathogenesis. It is released during migraine attacks, leading to vasodilation and transmission of pain signals. The development of CGRP-targeted monoclonal antibodies (erenumab, fremanezumab, galcanezumab, and eptinezumab) has provided novel tools for interrupting this pathway. However, CGRP also exerts protective vascular effects, such as counteracting vasoconstriction and maintaining endothelial function, raising theoretical concerns about potential cerebrovascular compromise when this pathway is inhibited.

Risk Factors

Major risk factors for cerebrovascular events in migraineurs include traditional cardiovascular risk factors (hypertension, diabetes, dyslipidemia), smoking, oral contraceptive use, and the presence of migraine with aura. The addition of biologic therapies necessitates careful risk-benefit assessment, particularly in patients with established cerebrovascular disease, uncontrolled hypertension, or other significant vascular comorbidities. Understanding patient-specific factors is critical to optimizing therapy and minimizing adverse outcomes.

Clinical Features

Cerebrovascular adverse events associated with migraine biologics are rare but clinically significant. Potential manifestations include ischemic stroke, transient ischemic attacks, and, hypothetically, impaired cerebrovascular response to physiological or pathological stressors. Clinicians should maintain vigilance for acute neurological deficits in patients receiving CGRP antagonists, especially those with pre-existing vascular risk factors. Notably, the large phase III clinical trials of these agents have excluded individuals with recent major cardiovascular or cerebrovascular events, limiting the generalizability of safety data to such populations.

Diagnosis

Diagnosis of cerebrovascular complications in the context of migraine biologic therapy relies on prompt clinical recognition of symptoms (e.g., sudden focal neurological deficits, altered mental status) and confirmatory neuroimaging (CT/MRI). Differentiating between migraine aura and ischemic events remains a diagnostic challenge, as both can present with transient neurological symptoms. A high index of suspicion is warranted in at-risk populations or when symptom patterns deviate from the patient’s typical migraine phenotype.

Treatment & Management

Management strategies focus on individualized risk assessment prior to initiating biologic therapy. Baseline evaluation should include a thorough history, assessment of cardiovascular and cerebrovascular risk factors, and, where appropriate, consultation with neurology or cardiology specialists. During therapy, clinicians should educate patients regarding warning signs of cerebrovascular events and ensure regular follow-up. In the event of suspected adverse events, immediate discontinuation of the biologic and appropriate acute stroke management protocols are indicated. Importantly, current data do not support routine cerebrovascular imaging for asymptomatic patients on CGRP monoclonal antibodies.

Recent Advances / Emerging Therapies

Emerging real-world data and post-marketing surveillance are beginning to elucidate the cerebrovascular safety profile of CGRP monoclonal antibodies. To date, major randomized controlled trials (STRIVE, ARISE, HALO, PROMISE, and others) have not demonstrated significant increases in cerebrovascular adverse events compared to placebo. Nevertheless, long-term registry studies and pharmacovigilance reports are essential to detect rare or delayed events, particularly in high-risk populations. Novel agents targeting alternative migraine pathways, such as PACAP antagonists and gepants, are under investigation, with ongoing evaluation of their vascular safety.

Guideline Recommendations

Current consensus guidelines recommend CGRP monoclonal antibodies for the prevention of episodic and chronic migraine in patients who have failed conventional preventive therapies. They advise caution in individuals with significant cerebrovascular or cardiovascular history, emphasizing the need for shared decision-making and individualized assessment of risks and benefits. Ongoing guideline updates will likely incorporate emerging long-term safety data as it becomes available.

Conclusion

The introduction of CGRP-targeted biologics marks a significant advance in migraine prophylaxis. Available evidence suggests a favorable cerebrovascular safety profile in the general migraine population, though data are limited in patients with established vascular disease. Careful patient selection, ongoing surveillance, and further research are required to fully elucidate the long-term cerebrovascular safety of these novel therapies. Clinicians should remain informed of evolving evidence to optimize patient outcomes and minimize potential risks.